News Release

Biotech Support Group introduces new product information and presents poster at the ASMS 2022 Conference on Mass Spectrometry & Allied Topics

MONMOUTH JUNCTION, NJ , June 22, 2022 -- Biotech Support Group presented new uses for its products in LC-MS analysis, and presented a poster with research collaborators at the ASMS 2022 Conference, in Minneapolis MN, June 5-9, 2022 . The information provided includes:

Albumin & IgG Removal Products

This product information sheet describes the BSG advantages for Albumin & IgG Removal and lists select references whereby these products were used for LC-MS analysis.


Click image to download

Hemoglobin Removal Products

This product information sheet describes the BSG advantages in Hemoglobin removal and lists select references whereby these products were used for LC-MS analysis.

Click image to download

Lipid Removal & Clarification

This product information sheet describes the BSG advantages for lipid removal and clarification and lists select references whereby these products were used for LC-MS analysis.

Click image to download

Proteomic Sample Prep & Enrichment

This product information sheet describes the common features for all of our products and their collective advantages in proteomic analysis. A select list of references is included describing how these advantages were used in referenced journal research.


Click image to download

NuGel™ bead formats support high throughput sample prep and automation

This product information sheet describes the NuGel™ features:

• 50 µm porous silica bead that is passivated through a proprietary coating exceedingly fast filtration and settling characteristics,

• perfectly suited to high throughput and automation

• customizable formats

• not derived from immuno-affinity

• selective depletion of Albumin, Albumin & lgG, and Hemoglobin.

Data using the DPX Technologies, high-throughput XTR tip format is provided.

Click image to download

Poster

Stromal conditioning correlations using Stroma Liquid Biopsy™ blood-based biomarkers and tumor tissue profiles

Matt Kuruc ¹; Cor J. Ravensbergen ²; Wilma E. Mesker ²; Rob Tollenaar ²; Yuri van der Burgt ²; Swapan Roy ¹

¹Biotech Support Group LLC, Monmouth Junction, NJ; ²Leiden University Medical Center, Leiden, Netherlands

Click image to download

Brief description: The concept of liquid biopsy has generated much scientific and commercial enthusiasm as it starts with a very accessible sample type - a body fluid, typically blood, rather than conventional solid tissue biopsy. Nevertheless, most current liquid biopsy efforts focus on genomic data which relies on a largely reductionist view that tumors form and progress only through the collection of its immortalized cells. While the current TNM staging system stratifies patients based on the extent of cancer spread, it is now overwhelmingly apparent that throughout cancer progression, tumor promoting inflammation is intrinsic to progressive disease. So although the TMN system provides guidance for clinical management, outcomes from local tumor excision at one end of the spectrum and adjuvant therapy at the other end, vary greatly among the variety of possible treatments within these stages. There remains great need for more personalized biomarkers to differentiate patient sub-populations and treatment options. For this, the supporting tumor microenvironments or stroma, must also be evaluated. Using proteomics and gene expression, we highlight the importance of the systemic inflammatory response to the presence of cancer anywhere in the body, largely derived from an unresolved innate immune response. Also, that the tumor-stroma microenvironment is an important prognostic parameter for patients with epithelial cancer types. We conclude that the stromal conditioning protein blueprint, as captured by the Stroma Liquid Biopsy™ panel, encompasses a more discreet stratification of the tumor and patient prognosis, and offers new insights into therapeutic strategies that might beneficially modulate the tumor-microenvironment.

“This was a very successful meeting for us as we were able to first and foremost show how all our sample prep and enrichment products are advantageously used in LC-MS analysis. Along with that, we were able to share very exciting developments from our research collaboration with Leiden University Medical Center, on our Stroma Liquid Biopsy™ platform. This panel of cancer-associated proteins necessitates the use of LC-MS to determine not only abundance levels but also functional attributes, which cannot be monitored by antigen presentation, aptamer or other like proteomic platforms. ”, states Dr. Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

For more information on BSG & Leiden University Medical Center Collaborative Research Agreement, see our joint press release:
https://www.biotechsupportgroup.com/Articles.asp?ID=570

For more information on the BSG complete line of Albumin & IgG Removal products , visit:
https://www.biotechsupportgroup.com/Albumin-Removal-s/307.htm

For more information on the BSG complete line of Hemoglobin Removal products, visit:

https://www.biotechsupportgroup.com/Hemoglobin-Removal-s/312.htm

For more information visit: Cleanascite™ Lipid Removal Reagent and Clarification, at
https://www.biotechsupportgroup.com/Lipid-Removal-s/316.htm

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, and HemogloBind™ and HemoVoid™ for hemoglobin removal. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to https://www.biotechsupportgroup.com

For Business Development, contact: Matthew Kuruc 732-274-2866 mkuruc@biotechsupportgroup.com